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Interleukin-33, a ligand for ST2/T1, has an important role in allergy, autoimmunity and inflammation. The role of IL-33/ST2
axis in cancer is not elucidated. Using metastatic breast cancer model we provide evidence that lack of ST2 signaling led
to reduced tumor growth and metastasis and enhanced anti-tumor immunity.
Interleukin-33 (IL-33) is a member of the
IL-1 family of cytokines and was identified
as a natural ligand for ST2/T1, an orphan
receptor in the IL-1R family. IL-33 is
produced as a biologically active full-
length molecule and may function as an
alarmin, when released after cell damage
or as nuclear IL-33 that reduces NF-kB–
triggered proinflammatory genes expres-
sion in non–IL-33 receptor–mediated
manner. Outside the cell, IL-33 acts as a
classical cytokine by binding to its recep-
tor, membrane bound ST2L (now desig-
nated IL-33Ra-chain) and IL-1R accessory
protein (IL-1RAp), leading to NFkB and
MAPK activation.
1,2 These findings high-
light the complex role of this multifunc-
tional cytokine.
IL-33 is constitutively expressed in
endothelial and epithelial cells of mucous
membranes, keratinocytes and fibroblasts.
ST2 (IL-33 receptor) exists as a full-length
membrane molecule (ST2L) and as
soluble, decoy variant ST2 (sST2). ST2L
is expressed by T cells (Th2, but not Th1
cells), NK and NKT cells, mast cells,
monocytes, dendritic cells and granulocytes.
ST2L was shown to be stably and selectively
expressed by murine Th2,
3 and also human
Th2 cells and NKT-like cells.
4 IL-33
polarizes naïve T cells to produce IL-4,
IL-5 and IL-13 (Th2-associated cytokines),
potently induces pro-inflammatory cyto-
kines and chemokines by mast cells and
eosinophils and amplifies polarization of
alternatively activated M2 macrophages.
Although ST2 (and IL-33) may act prim-
arily through a Th2-pathway, IL-33/ST2
axis can also promote Th1-type responses
depending on the local conditions, for
example, the presence or absence of IL-12.
1
IL-33 participates in many diseases with
dual, proinflammatory or protective roles
depending on the cellular and cytokine
context.
1 Namely, IL-33 has a protective
role during progression of atherosclerosis,
obesity, TNF-a mediated bone loss and
experimental fulminant hepatitis. We have
demonstrated that ST2 deficiency led
to more severe Con-A induced hepatitis
associated with increased numbers of
TNF-a,I F N - c and IL-17 producing liver
infiltrating mononuclear cells and increased
systemic pro-inflammatory cytokines.
Moreover, pre-treatment with IL-33 prior
to Con-A injection led to attenuation of
liver injury and increased liver CD4
+Foxp3
+
and IL-4 producing CD4+ T cells.
5
IL-33 is believed to be mainly involved
in allergen-specific Th2-type inflammation
and administration of neutralizing anti-
bodies against ST2 or IL-33 was shown to
attenuate eosinophilic pulmonary inflam-
mation in the murine model of allergic
asthma.
6 We have shown that deletion of
ST2 enhanced disease induction or severity
in several experimental models of organ
specific autoimmunity. Thus, ST22/2
mice were more sensitive to induction of
multiple low dose streptozotocin diabetes,
7
experimental allergic encephalomyelitis
(EAE) (unpublished data) and Con-A
induced fulminant hepatitis,
5 the findings
that suggest anti-inflammatory effects of IL-
33/ST2 axis. Indeed, Anthony et al.
8 have
elegantly shown that intravenous immuno-
globulins (ivIgs) suppress inflammation
through novel Th2 pathway that involves
IL-33. IgG crystallizable fragments stimu-
late the induction of IL-33 by dendritic
cells and macrophages which promote IL-4
producing basophils that increase the
expression of the inhibitory Fc receptor
FccRIIB on effector macrophages.
The data on the role of IL-33/ST2 axis
in cancer are lacking. We provided the
evidence that deletion of ST2 signaling
may enhance anti-tumor immune response
in a murine model of metastatic 4T1
breast carcinoma.
9 We showed delayed
appearance of palpable primary tumor,
slower tumor growth and reduced number
and size of metastatic colonies in lungs
and livers in ST22/2 mice. ST2 deletion
led to increased absolute numbers of
CD4+ and CD8+ T cells in local lymph
nodes and spleens after tumor challenge.
ST22/2 splenocytes, NK and CD8+ T
cells had enhanced cytotoxicity with
higher frequency of activated, NKp46+
CD107a
+ cells NK cells both constitu-
tively and after tumor inoculation.
ST22/2 mice had increased numbers
of IFN-c expressing NK cells, while
undetectable IL-10 producing NK cells.
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In addition, ST2 deficient mice had con-
stitutively higher percentages of activated
CD27
highCD11b
high NK cells, CD69
+ and
KLRG
- NK cells. In vivo depletion of
CD8+ or NK cells revealed the key role
for NK cells in enhanced anti-tumor
immunity in ST22/2 mice. ST22/2
mice had increased serum levels of IL-
17, IFN-c and TNF-a and decreased
serum IL-4 levels after tumor challenge.
Further, the lack of ST2 was associated
with constitutively decreased frequencies
of F4/80+CD206
+ alternatively activated
M2 macrophages in spleen (unpublished
data), that may potently suppresses
innate and adaptive anti-tumor immu-
nity. The increased anti-tumor immune
response observed in ST2-deficient mice
seems to be based mainly on two
independent mechanisms: Th1/Th17 cell
polarization and enhanced NK cell cyto-
toxic activity.
Based on our findings it could be specu-
lated that in the absence of ST2 immu-
nosuppressive Th2-type immune response
cannot be enhanced in the presence of
IL-33 from epithelial, endothelial or possi-
bly tumor cells. In this setting, IL-12
produced by classically activated M1
macrophages promote maturation of DCs
and consequently strong Th1/Th17 res-
ponse that activate tumoricidal NK, NKT
cells and CD8+ T cytotoxic lymphocytes
(Fig.1B). Hypothetically, if IL-33 is
overexpressed either endogenously or exo-
genously, its binding to ST2L activates
Th2 cells and promotes generation of rela-
tively immature dendritic cells that do not
produce IL-12p70 (Fig.1A). Immature
dendritic cells promote generation of T
regs and therefore facilitate tumor pro-
gression and metastasis. In addition, ST2
signaling could possibly induce the pro-
duction of thymic stromal lymphopoietin
(TSLP) by tumor cells. TSLP is known
to upregulate OX40L on dendritic cells
and induce IL-4 and more importantly
immunosuppressive IL-10 and IL-13 pro-
ducing Th2-cells that promote cancer
escape.
10
Our preliminary data show that exo-
genously administrated IL-33 enhanced
primary 4T1 tumor growth and inhibited
innate anti-tumor immunity. Several ques-
tions remains to be answered: whether
IL-33 facilitates cancer metastases, how
IL-33 affects proliferation, differentiation
and apoptosis of tumor cells, angiogenesis
and phenotype and function of tumor-
infiltrating immune cells.
Figure1. Hypothetical role of IL-33/ST2 axis in tumor growth and progression based on mouse mammary adenocarcinoma 4T1 cancer model. (A) The
effects of endogenous and also exogenous IL-33 in tumor-bearing hosts. IL-33 via its receptor ST2L activates Th2-polarized cells and generates relatively
immature dendritic cells that do not produce IL-12p70. Subsequently, ST2 signaling could possibly enhance production of thymic stromal lymphopoietin
(TSLP) by tumor cells which by upregulating OX40L on dendritic cells lead to induction of IL-4, and more importantly immunosuppressive IL-10 and IL-13
producing Th2-cells that promote cancer escape. Immature dendritic cells induce T regs that contribute to an immunosuppressive environment and
facilitate metastasis. (B) In the absence of ST2 (IL-33 receptor), IL-33 produced by epithelial cells and possibly tumor cells does not lead to the activation
of Th2-associated immunosuppressive response. Concomitantly, IL-12 produced by classically activated M1 macrophages lead to the maturation of DC,
strong IFN-c production by Th1 cells which activate tumoricidal NK, NKT cells and CD8+ T cytotoxic lymphocytes.
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